This also applies to compound semaglutide vs tirzepatide
When tested at a concentration of 10 pmol/l, both GLP-1(736) and GLP-1(936) inhibited glucagon secretion at 1 mmol/l glucose by ~50% (ESM Fig
8 These are all complaints for which there is a wide disparity between users reporting them and doctors acknowledging them as reasons for discontinuation
Korner to learn more about GLP-1 microdosing, how these medications work, and why patients shouldnt try this trend at home before speaking with their healthcare provider
[20] [9] If severe abdominal pain develops during GLP-1 agonist treatmentparticularly if it persists for several hours or is accompanied by repeated vomitingpatients should stop taking the medication and seek immediate medical assessment
Even clinicians who are not as familiar with these medications will ask me, 'I have a patient on Mounjaro who's not losing weight can we switch to Zepbound? without realizing its exactly the same drug. To complicate matters, pharmaceutical companies are quickly working on new drugs including triple agonists that target GLP-1, GIP and glucagon receptors as well as oral versions of each drug
